Join date: Apr 15, 2022

The Indian biosimilar market is expected to reach $35.7 billion by 2025, up from $11.8 billion in 2020, at a CAGR of 24.7 percent. India’s biologics market will grow at a compound annual growth rate (CAGR) of 22 percent to hit $12 billion by 2025.The market currently is dominated by simple biologics, such as therapies for the treatment of diabetes (insulin), oncology (EPO and mAbs), autoimmune, and cardiovascular diseases. Similar biologics for insulin and EPO enjoy 80 to 85 percent market share in India.

Read More: Lyocell Fiber Price, Aroma Sharing 2021, Cryocooler Price, Price of Zirconium, Colombia Palm Oil Market, Digital Forensics Market

More actions